Combination thymosin α1 and lymphoblastoid interferon treatment in chronic hepatitis C

Gut

Volumn 39, Issue 5, 1996, Pages 679-683

  Rasi, G ^a   DiVirgilio, D ^b   Mutchnick, M G ^d,e   Colella, F ^b   Sinibaldi Vallebona, P ^c   Pierimarchi, P ^a   Valli, B ^a   Garaci, E ^c  

^a CNR   (Italy)

^b Ospedale Figlie di San Camillo   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Chronic hepatitis; Combination treatment; HCV RNA; Interferon; Thymosin 1

Indexed keywords

ALPHAN1 INTERFERON; LYMPHOBLAST INTERFERON; THYMOSIN ALPHA1; VIRUS RNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030452149     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.39.5.679     Document Type: Article

References (39)

1. Esteban JI, Lopez-Talavera JC, Genesca J, Madoz P, Viladomiu L, Muniz E, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991; 115: 443-9.
2. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-905.
3. McQuillan GM, Alter MJ, Everhart JE. Viral Hepatitis. In: Everhart JE, ed. Digestive diseases in the United States: epidemiology and impact. US Department of Health and Human Services, Public Health Service, NIH, NIDDKD, Washington DC; US Government Printing Office, 1994; NIH publication no 94-1447, 127-56.
4. Davis GL, Baiart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant Interferon alpha. N Engl J Med 1989; 321: 1501-6.
5. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A non-B hepatitis. Gastroenterology 1991; 101: 497-502.
6. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A non-B chronic hepatitis: a meta-analysis of randomized clinical trials. J Hepatol 1991; 13: 192-9.
7. Garson JA, Brillanti S, Whitby K, Foli M, Deaville R, Masci C, et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol 1995; 45: 348-53.
8. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-6.
9. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-6.
10. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-62.
11. 2b for 60 weeks. Hepatology 1994; 19: 280-5.
12. Lindsay KL, Davis GL, Schiff E, Bodenheimer H, Balart L, Dienstag J, et al. Long-term response to higher doses of interferon (IFN) alpha-2b treatment of patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1993; 18: 106A.
13. Marcellin P, Routeau M, Martinat-Pergnoux M, Degos F, Duchatelle V, Boyer N, et al. Lack of benefit of escalating dosage of interferon alpha in patients with chronic hepatitis C. Gastroenterology 1995; 109: 156-65.
14. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirin plus interferon alpha for interferon alpha-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-7.
15. Boucher E, Jouanolle H, Andre P, Ruffault A, Guyader D, Moirand R, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients. Hepatology 1995; 21: 322-7.
16. Delich P, Hofmann CM, Luketic VA, Purdum PP III, Sanval AJ, Mills AS, et al. Treatment of chronic hepatitis C (HCV) with ursodeoxycholic acid (UDCA) in patients who failed interferon (IFN) therapy. Gastroenterology 1995; 108: A1057.
17. Mutchnick MG, Ehrinpreis MN, Kinzie JL, Peleman RR. Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents. Antiviral Res 1994; 24: 245-57.
18. Rezakovic I, Zavaglia C, Bottelli R, Ideo G. A pilot study of thymosin alpha 1 therapy in chronic active hepatitis C. Hepatology 1993; 18: A252.
19. Sherman KE, Sjogren MH, Creager RL, Freeman S, O'Brear J, Noot S, et al. Hepatitis C RNA response to combined therapy with thymosin alpha-1 and interferon. Hepatology 1994; 20: A207.
20. Okamoto H, Kurai K, Okada SC, Yamamoto K, Lizuka H, Tanaka T, et al. Full-length sequences of a hepatic C virus genome having poor homology to reported isolates: comparison study of four distinct genotypes. Virology 1992; 188: 331-41.
21. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
22. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87: 6547-9.
23. Nousbaum J-B, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C, et al. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122: 161-8.
24. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-9.
25. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.
26. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, et al. Efficacy of interferon alpha therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995; 22: 1351-4.
27. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570-83.
28. Gonzalez-Peralta RP, Davis GL, Lau JYN. Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J Hepatol 1994; 21: 255-9.
29. Koziel MJ, Dudley D, Wong JT, Dienstag J. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992; 149: 3339-44.
30. Liaw Y-F, Lee C-S, Tsai S-L, Liaw B-W, Chen T-C, Sheen I-S, et al. T cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology 1995; 22: 1368-73.
31. Zeldis JB, Jensen P. Hepatitis C virus pathogenicity: the corner pieces of the jigsaw puzzle are found. Gastroenterology 1994; 106: 1118-20.
32. Naylor PH, Mutchnick MG. Thymus derived peptides in the treatment of viral chronic hepatitis. Dig Dis (in press).
33. 1 and interferon α. Hepatology 1994; 20: 284A.
34. Farhat BA, Marinos G, Daniels HM, Naoumov NV, Williams R. Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the mangement of chronic hepatitis B. J Hepatol 1995; 23: 21-7.
35. Cianciara J, Laskus T. Thymic factor X treatment of chronic hepatitis B. (letter). Hepatology 1992; 16: 1507-8.
36. Burstein Y, Burcher V, Pecht M, Trainin N. Thymic humoral factor-γ2: purification and amino acid sequence of an immunomodulatory peptide from calf thymus. Biochemsitry 1988; 27: 4066-71.
37. Daniels HM, O'Toole A, Hussein MJ, Corridori S, Alexander GJM, Williams R. THF γ2 stimulates cytokine release by peripheral blood mononuclear cells of patients with chronic hepatitis B virus infection. J Hepatol 1994; 20: 370-5.
38. 1 therapy in the treatment of chronic hepatitis B. J Viral Hepatol 1996; 3: 191-6.
39. Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, et al. Thymosin treatment of chronic hepatitis B. A placebo-controlled pilot trial. Hepatology 1991; 14: 409-15.